Analysts’ Viewpoint
Rise in usage of smartphones and increase in prevalence of chronic diseases are expected to propel the digital therapeutics market size during the forecast period. Growth in healthcare expenditures and surge in investment in R&D are likely to offer lucrative opportunities to vendors in the global digital therapeutics industry.
Emergence of the COVID-19 pandemic has led to the rapid deployment of remote patient monitoring systems and telemedicine. Growth in accessibility of wearable technology and user-friendly mobile applications and presence of favorable reimbursement policies are estimated to contribute to the digital therapeutics market growth in the near future. Concerns regarding data privacy, legality, and robust clinical proofs are anticipated to limit demand for digital therapeutics during the forecast period.
The digital therapeutics market, a part of the rapidly growing healthcare industry, focuses on the use of software-based interventions to prevent, manage, or treat various medical conditions. These interventions are intended to supplement conventional medical treatments and are usually provided through internet platforms, wearable technologies, and mobile applications.
The affordability of digital health technology for both patients and providers and increase in adoption of smartphones in developed and developing economies are propelling the digital therapeutics market expansion. According to Kepios, a strategy consultancy, there were 5 billion internet users around the world in April 2022, which accounted for 63% of the global population.
Chronic illnesses, such as diabetes, heart disease, and respiratory conditions, are becoming increasingly common. Improved patient outcomes can be achieved by using digital therapeutics as a convenient and efficient means of managing certain illnesses. Surge in need for affordable solutions and rise in healthcare expenditure are boosting the digital therapeutics market development. Digital therapeutics provide self-management tools, individualized treatment regimens, and remote monitoring to lower healthcare costs.
The way people interact with and access digital technologies, including healthcare solutions, has changed significantly as a result of the widespread adoption of smartphones. For a considerable segment of the world's population, smartphones have become an essential component of everyday existence. These gadgets provide a practical and reachable platform for interventions using digital therapeutics. Digital therapeutics-specific mobile applications give users quick access to self-management tools, remote monitoring, learning materials, and tailored interventions.
People can interact with digital therapies anytime and anywhere due to the convenience and portability of smartphones, which gives them the ability to take charge of their health and well-being. Additionally, smartphones provide real-time feedback, reminders, and push notifications, which improve patient engagement and treatment plan adherence. Digital therapeutic solutions can collect useful health data, including activity levels, sleep patterns, and physiological measurements, by utilizing smartphone sensors and capabilities. Healthcare providers can use this data to track progress, personalize interventions, and gain insights.
Chronic diseases, such as diabetes, cardiovascular diseases, respiratory disorders, and mental health conditions, are on the rise globally. These conditions pose significant challenges to healthcare systems as they require long-term management and can lead to complications and reduced quality of life.
Digital therapeutics provide a promising solution by offering convenient, accessible, and personalized interventions for chronic disease management. Through mobile applications, wearable devices, and online platforms, digital therapeutics enable individuals to monitor their health, receive real-time feedback, access educational resources, and adhere to treatment plans.
Rise in prevalence of chronic diseases has created a need for innovative approaches that can improve patient outcomes, enhance self-management, and reduce healthcare costs associated with hospitalizations and emergency visits. Digital therapeutics address these needs by empowering patients to actively participate in their care, promoting behavior change, and providing continuous support between healthcare visits.
According to the latest digital therapeutics market trends, the treatment/care application segment held significant share in 2022. Software-based interventions can be employed for the treatment and care of various medical conditions including substance abuse, mental health issues, diabetes, respiratory disorders, and cardiovascular diseases.
Rise in need for efficient and easily accessible treatment options led by a surge in the incidence of chronic diseases worldwide is propelling the segment. Personalized interventions provided by digital therapeutics can help patients monitor their health, manage their conditions, and follow their treatment regimens. These strategies can include anything from online coaching and cognitive behavioral therapy to symptom monitoring and medication reminders.
Technological developments, such as wearables and smartphone applications, have made it possible to provide patients with treatment and care right at their fingertips. Through the provision of individualized recommendations, educational materials, and real-time feedback, these digital tools enable people to take an active role in their own care.
According to the latest digital therapeutics market analysis, the B2B end-user segment accounted for largest share in 2022. B2B refers to the commercial relationships between digital therapeutics companies and other businesses such as healthcare providers, pharmaceutical companies, employers, and insurance companies.
Rise in awareness regarding the potential of digital therapeutics in elevating patient care is driving the segment. Healthcare providers are collaborating with digital therapeutics companies to seamlessly integrate digital solutions into current healthcare systems in order to improve patient management.
Pharmaceutical companies are collaborating with digital therapeutics startups to enhance their pharmacological therapies. Digital therapeutics can enhance medication adherence, give patients more support, and collect empirical data on the efficacy of treatments. This partnership between digital therapeutics companies and pharmaceutical companies creates new opportunities for patient care that are both comprehensive and individualized.
According to the latest digital therapeutics market forecast, North America is expected to hold largest share from 2023 to 2031. Rise in investment in R&D activities is fueling the market dynamics of the region. North America, particularly the U.S., is known for its advancements in technology and digital innovation. The region has a robust infrastructure, a high level of digital literacy, and a favorable ecosystem for the development and adoption of digital therapeutics solutions.
Surge in funding for digital therapeutics is propelling the market statistics in North America. Government programs, private equity funds, and venture capital firms are contributing to the creation and regionalization of digital therapeutics solutions. The U.S. is encouraging collaborations between digital therapeutics companies, healthcare providers, and research institutions. Thus, rise in collaborations among digital therapeutics startups, pharmaceutical giants, and technology companies is driving the digital therapeutics revenue in North America
Patients, payers, and healthcare providers in North America are increasingly adopting digital therapeutics. The region is highly digitally literate and has a culture that embraces technology to improve healthcare. A well-defined regulatory framework for digital therapeutics has been established in the U.S. The Food and Drug Administration (FDA) has established procedures and guidelines for assessing and approving digital therapeutics. Digital therapeutics companies can enter the market more easily and with greater confidence due to this regulatory clarity.
The global industry is consolidated, with the presence of a small number of leading players. Most players are adopting product portfolio expansion M&A strategies to increase their digital therapeutics market share.
Noom, Inc., Teladoc Health, Inc., Omada Health Inc., WellDoc Inc., Pear Therapeutics Inc., CogniFit, Ginger, Propeller Health, 2Morrow Inc., Canary Health, Click Therapeutics Inc., Akili, Cognoa, and Wellthy Therapeutics Pvt. Ltd. are prominent players operating in this market.
Each of these players has been profiled in the digital therapeutics market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
| Attribute | Detail |
|---|---|
| Market Value in 2022 | US$ 4.5 Bn |
| Market Forecast Value in 2031 | US$ 43.2 Bn |
| Growth Rate (CAGR) | 28.6% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2022 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
It was valued at US$ 4.5 Bn in 2022
It is projected to reach US$ 43.2 Bn by the end of 2031
It is estimated to be 28.6% from 2023 to 2031
Rise in usage of smartphones and increase in prevalence of chronic diseases
North America is projected to record the highest demand during the forecast period
Noom, Inc., Teladoc Health, Inc., Omada Health Inc., WellDoc Inc., Pear Therapeutics Inc., CogniFit, Ginger, Propeller Health, 2Morrow Inc., Canary Health, Click Therapeutics Inc., Akili, Cognoa, and Wellthy Therapeutics Pvt. Ltd.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Digital Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Application Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Digital Therapeutics Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Disease Prevalence & Incidence Rate Globally with Key Countries
5.2. Key Industry Events
5.3. Technological Advancement
5.4. Insights on Digital therapeutics (DTx) for Disease Management
5.5. COVID-19 Pandemic Impact on Industry (Value Chain And Short/Mid/Long Term Impact)
6. Global Digital Therapeutics Market Analysis and Forecast, by Application
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Application, 2017–2031
6.3.1. Treatment/Care
6.3.1.1. Diabetes
6.3.1.2. Cardiovascular Diseases
6.3.1.3. Central Nervous System Diseases
6.3.1.4. Respiratory Diseases
6.3.1.5. Musculoskeletal Diseases
6.3.1.6. Medication Adherence
6.3.1.7. Others
6.3.2. Preventive
6.3.2.1. Prediabetes
6.3.2.2. Obesity
6.3.2.3. Smoking Cessation
6.3.2.4. Others
6.4. Market Attractiveness Analysis, by Application
7. Global Digital Therapeutics Market Analysis and Forecast, by End-user
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by End-user, 2017–2031
7.3.1. B2B
7.3.1.1. Providers
7.3.1.2. Payers
7.3.1.3. Employers
7.3.1.4. Pharmaceutical Companies
7.3.1.5. Others
7.3.2. B2C
7.3.2.1. Patients
7.3.2.2. Caregivers
7.4. Market Attractiveness Analysis, by End-user
8. Global Digital Therapeutics Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region
9. North America Digital Therapeutics Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Application, 2017–2031
9.2.1. Treatment/Care
9.2.1.1. Diabetes
9.2.1.2. Cardiovascular Diseases
9.2.1.3. Central Nervous System Diseases
9.2.1.4. Respiratory Diseases
9.2.1.5. Musculoskeletal Diseases
9.2.1.6. Medication Adherence
9.2.1.7. Others
9.2.2. Preventive
9.2.2.1. Prediabetes
9.2.2.2. Obesity
9.2.2.3. Smoking Cessation
9.2.2.4. Others
9.3. Market Value Forecast, by End-user, 2017–2031
9.3.1. B2B
9.3.1.1. Providers
9.3.1.2. Payers
9.3.1.3. Employers
9.3.1.4. Pharmaceutical Companies
9.3.1.5. Others
9.3.2. B2C
9.3.2.1. Patients
9.3.2.2. Caregivers
9.3.3. Commercial
9.4. Market Value Forecast, by Country, 2017–2031
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Application
9.5.2. By End-user
9.5.3. By Country
10. Europe Digital Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Application, 2017–2031
10.2.1. Treatment/Care
10.2.1.1. Diabetes
10.2.1.2. Cardiovascular Diseases
10.2.1.3. Central Nervous System Diseases
10.2.1.4. Respiratory Diseases
10.2.1.5. Musculoskeletal Diseases
10.2.1.6. Medication Adherence
10.2.1.7. Others
10.2.2. Preventive
10.2.2.1. Prediabetes
10.2.2.2. Obesity
10.2.2.3. Smoking Cessation
10.2.2.4. Others
10.3. Market Value Forecast, by End-user, 2017–2031
10.3.1. B2B
10.3.1.1. Providers
10.3.1.2. Payers
10.3.1.3. Employers
10.3.1.4. Pharmaceutical Companies
10.3.1.5. Others
10.3.2. B2C
10.3.2.1. Patients
10.3.2.2. Caregivers
10.3.3. Commercial
10.4. Market Value Forecast, by Country/Sub-region, 2017–2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Application
10.5.2. By End-user
10.5.3. By Country/Sub-region
11. Asia Pacific Digital Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Application, 2017–2031
11.2.1. Treatment/Care
11.2.1.1. Diabetes
11.2.1.2. Cardiovascular Diseases
11.2.1.3. Central Nervous System Diseases
11.2.1.4. Respiratory Diseases
11.2.1.5. Musculoskeletal Diseases
11.2.1.6. Medication Adherence
11.2.1.7. Others
11.2.2. Preventive
11.2.2.1. Prediabetes
11.2.2.2. Obesity
11.2.2.3. Smoking Cessation
11.2.2.4. Others
11.3. Market Value Forecast, by End-user, 2017–2031
11.3.1. B2B
11.3.1.1. Providers
11.3.1.2. Payers
11.3.1.3. Employers
11.3.1.4. Pharmaceutical Companies
11.3.1.5. Others
11.3.2. B2C
11.3.2.1. Patients
11.3.2.2. Caregivers
11.3.3. Commercial
11.4. Market Value Forecast, by Country/Sub-region, 2017–2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Application
11.5.2. By End-user
11.5.3. By Country/Sub-region
12. Latin America Digital Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Application, 2017–2031
12.2.1. Treatment/Care
12.2.1.1. Diabetes
12.2.1.2. Cardiovascular Diseases
12.2.1.3. Central Nervous System Diseases
12.2.1.4. Respiratory Diseases
12.2.1.5. Musculoskeletal Diseases
12.2.1.6. Medication Adherence
12.2.1.7. Others
12.2.2. Preventive
12.2.2.1. Prediabetes
12.2.2.2. Obesity
12.2.2.3. Smoking Cessation
12.2.2.4. Others
12.3. Market Value Forecast, by End-user, 2017–2031
12.3.1. B2B
12.3.1.1. Providers
12.3.1.2. Payers
12.3.1.3. Employers
12.3.1.4. Pharmaceutical Companies
12.3.1.5. Others
12.3.2. B2C
12.3.2.1. Patients
12.3.2.2. Caregivers
12.3.3. Commercial
12.4. Market Value Forecast, by Country/Sub-region, 2017–2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Application
12.5.2. By End-user
12.5.3. By Country/Sub-region
13. Middle East & Africa Digital Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Application, 2017–2031
13.2.1. Treatment/Care
13.2.1.1. Diabetes
13.2.1.2. Cardiovascular Diseases
13.2.1.3. Central Nervous System Diseases
13.2.1.4. Respiratory Diseases
13.2.1.5. Musculoskeletal Diseases
13.2.1.6. Medication Adherence
13.2.1.7. Others
13.2.2. Preventive
13.2.2.1. Prediabetes
13.2.2.2. Obesity
13.2.2.3. Smoking Cessation
13.2.2.4. Others
13.3. Market Value Forecast, by End-user, 2017–2031
13.3.1. B2B
13.3.1.1. Providers
13.3.1.2. Payers
13.3.1.3. Employers
13.3.1.4. Pharmaceutical Companies
13.3.1.5. Others
13.3.2. B2C
13.3.2.1. Patients
13.3.2.2. Caregivers
13.3.3. Commercial
13.4. Market Value Forecast, by Country/Sub-region, 2017–2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Application
13.5.2. By End-user
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player – Competition Matrix (By Tier and Size of Companies)
14.2. Market Share Analysis, by Company (2022)
14.3. Company Profiles
14.3.1. Noom, Inc.
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Product Portfolio
14.3.1.3. Financial Overview
14.3.1.4. SWOT Analysis
14.3.1.5. Strategic Overview
14.3.2. Teladoc Health, Inc.
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Product Portfolio
14.3.2.3. Financial Overview
14.3.2.4. SWOT Analysis
14.3.2.5. Strategic Overview
14.3.3. Omada Health Inc.
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Product Portfolio
14.3.3.3. Financial Overview
14.3.3.4. SWOT Analysis
14.3.3.5. Strategic Overview
14.3.4. WellDoc Inc.
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Product Portfolio
14.3.4.3. Financial Overview
14.3.4.4. SWOT Analysis
14.3.4.5. Strategic Overview
14.3.5. Pear Therapeutics Inc.
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Product Portfolio
14.3.5.3. Financial Overview
14.3.5.4. SWOT Analysis
14.3.5.5. Strategic Overview
14.3.6. CogniFit
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Product Portfolio
14.3.6.3. Financial Overview
14.3.6.4. SWOT Analysis
14.3.6.5. Strategic Overview
14.3.7. Ginger
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Product Portfolio
14.3.7.3. Financial Overview
14.3.7.4. SWOT Analysis
14.3.7.5. Strategic Overview
14.3.8. Propeller Health
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Product Portfolio
14.3.8.3. Financial Overview
14.3.8.4. SWOT Analysis
14.3.8.5. Strategic Overview
14.3.9. 2Morrow Inc.
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Product Portfolio
14.3.9.3. Financial Overview
14.3.9.4. SWOT Analysis
14.3.9.5. Strategic Overview
14.3.10. Canary Health
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Product Portfolio
14.3.10.3. Financial Overview
14.3.10.4. SWOT Analysis
14.3.10.5. Strategic Overview
14.3.11. Click Therapeutics Inc.
14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.11.2. Product Portfolio
14.3.11.3. Financial Overview
14.3.11.4. SWOT Analysis
14.3.11.5. Strategic Overview
14.3.12. Akili
14.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.12.2. Product Portfolio
14.3.12.3. Financial Overview
14.3.12.4. SWOT Analysis
14.3.12.5. Strategic Overview
14.3.13. Cognoa
14.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.13.2. Product Portfolio
14.3.13.3. Financial Overview
14.3.13.4. SWOT Analysis
14.3.13.5. Strategic Overview
14.3.14. Wellthy Therapeutics Pvt. Ltd.
14.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.14.2. Product Portfolio
14.3.14.3. Financial Overview
14.3.14.4. SWOT Analysis
14.3.14.5. Strategic Overview
14.3.15. Other Prominent Players
List of Tables
Table 01: Global Digital Therapeutics Market Value (US$ Bn) Forecast, by Application, 2017–2031
Table 02: Global Digital Therapeutics Market Value (US$ Bn) Forecast, by End-user, 2017–2031
Table 03: Global Digital Therapeutics Market Value (US$ Bn) Forecast, by Region, 2017–2031
Table 04: North America Digital Therapeutics Market Value (US$ Bn) Forecast, by Application, 2017–2031
Table 05: North America Digital Therapeutics Market Value (US$ Bn) Forecast, by End-user, 2017–2031
Table 06: North America Digital Therapeutics Market Value (US$ Bn) Forecast, by Country, 2017–2031
Table 07: Europe Digital Therapeutics Market Value (US$ Bn) Forecast, by Application, 2017–2031
Table 08: Europe Digital Therapeutics Market Value (US$ Bn) Forecast, by End-user, 2017–2031
Table 09: Europe Digital Therapeutics Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2031
Table 10: Asia Pacific Digital Therapeutics Market Value (US$ Bn) Forecast, by Application, 2017–2031
Table 11: Asia Pacific Digital Therapeutics Market Value (US$ Bn) Forecast, by End-user, 2017–2031
Table 12: Asia Pacific Digital Therapeutics Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2031
Table 13: Latin America Digital Therapeutics Market Value (US$ Bn) Forecast, by Application, 2017–2031
Table 14: Latin America Digital Therapeutics Market Value (US$ Bn) Forecast, by End-user, 2017–2031
Table 15: Latin America Digital Therapeutics Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2031
Table 16: Middle East & Africa Digital Therapeutics Market Value (US$ Bn) Forecast, by Application, 2017–2031
Table 17: Middle East & Africa Digital Therapeutics Market Value (US$ Bn) Forecast, by End-user, 2017–2031
Table 18: Middle East & Africa Digital Therapeutics Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2031
List of Figures
Figure 01: Global Digital Therapeutics Market Value (US$ Bn) Forecast, 2017–2031
Figure 02: Global Digital Therapeutics Market Value Share Analysis, by Application, 2022 and 2031
Figure 03: Global Digital Therapeutics Market Attractiveness Analysis, by Application, 2023–2031
Figure 04: Global Digital Therapeutics Market Value Share Analysis, by End-user, 2022 and 2031
Figure 05: Global Digital Therapeutics Market Attractiveness Analysis, by End-user, 2023–2031
Figure 06: Global Digital Therapeutics Market Value Share Analysis, by Region, 2022 and 2031
Figure 07: Global Digital Therapeutics Market Attractiveness Analysis, by Region, 2023–2031
Figure 08: North America Digital Therapeutics Market Value (US$ Bn) Forecast, 2017–2031
Figure 09: North America Digital Therapeutics Market Value Share Analysis, by Application, 2022 and 2031
Figure 10: North America Digital Therapeutics Market Attractiveness Analysis, by Application, 2023–2031
Figure 11: North America Digital Therapeutics Market Value Share Analysis, by End-user, 2022 and 2031
Figure 12: North America Digital Therapeutics Market Attractiveness Analysis, by End-user, 2023–2031
Figure 13: North America Digital Therapeutics Market Value Share Analysis, by Country, 2022 and 2031
Figure 14: North America Digital Therapeutics Market Attractiveness Analysis, by Country, 2023–2031
Figure 15: Europe Digital Therapeutics Market Value (US$ Bn) Forecast, 2017–2031
Figure 16: Europe Digital Therapeutics Market Value Share Analysis, by Application, 2022 and 2031
Figure 17: Europe Digital Therapeutics Market Attractiveness Analysis, by Application, 2023–2031
Figure 18: Europe Digital Therapeutics Market Value Share Analysis, by End-user, 2022 and 2031
Figure 19: Europe Digital Therapeutics Market Attractiveness Analysis, by End-user, 2023–2031
Figure 20: Europe Digital Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 21: Europe Digital Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 22: Asia Pacific Digital Therapeutics Market Value (US$ Bn) Forecast, 2017–2031
Figure 23: Asia Pacific Digital Therapeutics Market Value Share Analysis, by Application, 2022 and 2031
Figure 24: Asia Pacific Digital Therapeutics Market Attractiveness Analysis, by Application, 2023–2031
Figure 25: Asia Pacific Digital Therapeutics Market Value Share Analysis, by End-user, 2022 and 2031
Figure 26: Asia Pacific Digital Therapeutics Market Attractiveness Analysis, by End-user, 2023–2031
Figure 27: Asia Pacific Digital Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 28: Asia Pacific Digital Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 29: Latin America Digital Therapeutics Market Value (US$ Bn) Forecast, 2017–2031
Figure 30: Latin America Digital Therapeutics Market Value Share Analysis, by Application, 2022 and 2031
Figure 31: Latin America Digital Therapeutics Market Attractiveness Analysis, by Application, 2023–2031
Figure 32: Latin America Digital Therapeutics Market Value Share Analysis, by End-user, 2022 and 2031
Figure 33: Latin America Digital Therapeutics Market Attractiveness Analysis, by End-user, 2023–2031
Figure 34: Latin America Digital Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 35: Latin America Digital Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 36: Middle East & Africa Digital Therapeutics Market Value (US$ Bn) Forecast, 2017–2031
Figure 37: Middle East & Africa Digital Therapeutics Market Value Share Analysis, by Application, 2022 and 2031
Figure 38: Middle East & Africa Digital Therapeutics Market Attractiveness Analysis, by Application, 2023–2031
Figure 39: Middle East & Africa Digital Therapeutics Market Value Share Analysis, by End-user, 2022 and 2031
Figure 40: Middle East & Africa Digital Therapeutics Market Attractiveness Analysis, by End-user, 2023–2031
Figure 41: Middle East & Africa Digital Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 42: Middle East & Africa Digital Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 43: Global Digital Therapeutics Market Share Analysis, by Company, 2022
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Digital Therapeutics Market
